Aardvark Therapeutics (NASDAQ:AARD) Posts Quarterly Earnings Results

Aardvark Therapeutics (NASDAQ:AARD) posted its quarterly earnings results on Monday. The company reported ($0.81) EPS for the quarter, FiscalAI reports.

Aardvark Therapeutics Price Performance

NASDAQ:AARD opened at $4.07 on Tuesday. The stock has a market cap of $88.60 million and a P/E ratio of -1.92. The business’s 50-day moving average price is $10.82 and its two-hundred day moving average price is $11.72. Aardvark Therapeutics has a twelve month low of $4.01 and a twelve month high of $17.94.

Analysts Set New Price Targets

A number of analysts recently issued reports on AARD shares. William Blair began coverage on Aardvark Therapeutics in a research note on Friday, December 12th. They set an “outperform” rating on the stock. Raymond James Financial reaffirmed a “strong-buy” rating and set a $47.00 target price on shares of Aardvark Therapeutics in a report on Monday, January 12th. B. Riley Financial initiated coverage on shares of Aardvark Therapeutics in a report on Wednesday, January 28th. They issued a “buy” rating and a $32.00 price target on the stock. HC Wainwright restated a “neutral” rating on shares of Aardvark Therapeutics in a research report on Monday, March 2nd. Finally, Royal Bank Of Canada cut shares of Aardvark Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price objective for the company from $18.00 to $6.00 in a research note on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $25.09.

Institutional Investors Weigh In On Aardvark Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd bought a new stake in Aardvark Therapeutics during the fourth quarter valued at approximately $335,000. Superstring Capital Management LP bought a new stake in shares of Aardvark Therapeutics during the 4th quarter worth $912,000. Millennium Management LLC grew its position in Aardvark Therapeutics by 51.2% in the fourth quarter. Millennium Management LLC now owns 483,340 shares of the company’s stock worth $6,344,000 after acquiring an additional 163,717 shares in the last quarter. Balyasny Asset Management L.P. bought a new position in Aardvark Therapeutics in the fourth quarter valued at $181,000. Finally, Bridgeway Capital Management LLC raised its position in Aardvark Therapeutics by 22.7% during the fourth quarter. Bridgeway Capital Management LLC now owns 27,000 shares of the company’s stock valued at $354,000 after purchasing an additional 5,000 shares in the last quarter.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.